RxDoctor Payments Data

Andrew Hilburger, MD

Neurology · Batavia, NYNPI 1649230517

Payments from drug & device makers

$7,710in general payments, 2019–2025

Across 446 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$1K
  • AbbVie$989
  • Amgen$566
  • Teva Pharmaceuticals USA, Inc.$464
  • Pfizer$415
  • Neurocrine Biosciences, Inc.$395
  • plus $4K from 51 others
$490in research payments, 2019–2025

Across 1 payment — averaging $490.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Avanir Pharmaceuticals, Inc.$490

What the payments were for

  • Speaking & faculty fees$3765%
  • Food & beverage$7,23494%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi40$1,147
AbbVie(2 entities)65$989
Amgen32$566
Teva Pharmaceuticals USA, Inc.32$464
Pfizer35$415
Neurocrine Biosciences, Inc.24$395
Lilly USA, LLC16$272
EMD Serono, Inc.16$259
Avanir Pharmaceuticals, Inc.20$238
UCB, Inc.12$225
SK Life Science, Inc.8$175
Johnson & Johnson(2 entities)3$151
Scilex Pharmaceuticals Inc.9$143
Biogen9$134
TG Therapeutics, Inc.7$133
Eisai Inc.7$132
Genentech USA, Inc.6$118
Lundbeck LLC6$116
Acorda Therapeutics, Inc7$114
Neurelis, Inc.5$110
Axsome Therapeutics, Inc.6$104
Livanova USA, Inc.5$95
Novartis6$87
GE HealthCare8$87
Jazz Pharmaceuticals Inc.5$85
Amneal Pharmaceuticals LLC4$77
Bristol Myers Squibb4$63
CSL Behring2$54
Sunovion Pharmaceuticals Inc.6$53
Acadia Pharmaceuticals Inc3$51
AstraZeneca3$46
Vanda Pharmaceuticals Inc.2$46
Grifols USA, LLC2$45
Upsher-smith Laboratories LLC3$40
Alnylam Pharmaceuticals Inc.2$40
Impel Pharmaceuticals Inc.2$37
Argenx US, Inc.2$36
Supernus Pharmaceuticals, Inc.1$32
Tonix Medicines, Inc.2$32
Biohaven Pharmaceutical Holding Company Ltd.2$32
Otsuka America Pharmaceutical, Inc.1$25
Abbott1$25
E.r. Squibb & Sons, L.L.C.1$21
ANI Pharmaceuticals, Inc.1$21
Merz Pharmaceuticals, LLC1$21
Banner Life Sciences, LLC1$19
Novo Nordisk1$18
Collegium Pharmaceutical, Inc.1$17
Currax Pharmaceuticals LLC1$16
Adamas Pharmaceuticals, Inc.1$15
Assertio Therapeutics, Inc.1$14
Biohaven Pharmaceuticals, Inc.1$13
Takeda Pharmaceuticals U.S.A., Inc.1$13
Kyowa Kirin, Inc.1$12
Promius Pharma LLC1$12
Vertical Pharmaceuticals, LLC1$11
Neurology Practice Consortium GPO, LLC1$0

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,710 in reported general payments places this provider in the 65th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$248,018
Medicare patients
266
Services billed
10,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate47$83,886
BriviactBrivaracetam32$46,368
Aimovig AutoinjectorErenumab-Aooe55$43,118
NuedextaDextromethorphan Hbr/Quinidine18$21,117
LamictalLamotrigine14$20,375
Effexor XrVenlafaxine Hcl14$11,868
Sumatriptan Succinate88$11,069
Tegretol XrCarbamazepine37$11,063
UbrelvyUbrogepant11$9,902
TegretolCarbamazepine13$8,099
Pregabalin182$7,127
Levetiracetam224$6,384
Depakote ErDivalproex Sodium13$5,677
Carbamazepine ErCarbamazepine31$5,432
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone39$3,842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Effexor Xr, Dilantin$415$97,53582 claims
UCB, Inc.Briviact$225$46,36832 claims
Avanir Pharmaceuticals, Inc.Nuedexta$238$21,11718 claims
AbbVieUbrelvy$989$9,90211 claims
Upsher-smith Laboratories LLCTopiramate$40$1,642158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,623 neurology providers in New York.

Other neurology in Batavia

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →